Preventive Measures for your Prostate Saw Palmetto Saw Palmetto is a supplemental extract used to treat the symptoms of benign prostate hyperplasia (BNP), or non-cancerous prostate enlargement. It has pharmacologic effects similar to finasteride and has been used as a preventive measure against prostate cancer. The use of saw palmetto extracts can reduce the size of the prostate. Some medical practitioners, in fact, recommend their patients take 3 tablets of saw palmetto daily to reverse potential prostate enlargement, starting by the age of 30. The active element comes from the fruit of the American palm tree. More and more researchers are proving the
efficacy of saw palmetto in comparison to medical
Prostate cancer prevention Caring for the prostate
drugs such as finasteride. The herbal supplement is
should not begin when you have an enlarged prostate,
certainly much safer with fewer side effects, cheaper
but when it’s normal and healthy. Today many
researchers are looking for non-invasive ways to
control the enlargement of the prostate so that it does
In theory, saw palmetto functions by interfering with
not develop into prostate cancer later on. Medical
the conversion of testosterone to dihydrotestosterone
interventions and management are all focused on the
(DHT), leading to decreased glandular cell activity
cause of the benign prostate hyperplasia (BPH), the
that enlarges the prostate. In addition, saw palmetto
severity of the obstruction, and the patient’s other
may directly block the ability of DHT to stimulate
conditions. It’s focused on curing a disease not
prostate cell growth. It should not be used with
preventing it. Although there is great importance in
finasteride, dutasteride, or any medication containing
immediate medical interventions to manage the
enlarged prostate so it does not develop into prostate
cancer, we must also focus on how we can avoid it.
Provenge
A new medical intervention is still under clinical trial
Today most pharmacologic treatments work around
and research. Many are hoping that it can become
the principle of blocking certain hormones believed
another means of treating prostate enlargement. The
to be the root cause of the problem. The use of alpha-
action of Provenge is similar to the action of a
adrenergic blockers and 5-alpha-reductase inhibitors
vaccine. Initially, a sample of the patient’s blood is
to minimize the prostate has been medically
taken. Then cell components in his blood are
accepted. Alpha adrenergic blockers are known to
combined with a weaker prostate cancer strain.
relax the smooth muscle of the bladder neck and
Together, with a stimulant, the blood is injected back
prostate. This smoothening of the muscle blockade
into his system. The main goal of the vaccine is to
improves urine excretion and relieves benign prostate
trigger a reaction and formation of antibodies that can
specifically target and engulf prostate cancer cells.
The concept behind the treatment is to elicit a
Because of this, one method of treatment involves
response from the immune system so it will make
hormonal manipulation with anti-androgen agents. In
antibodies. During the process of developing this
clinical studies, inhibitors such as finasteride have
specific treatment, many researchers recommend that
been effective in preventing the conversion of
volunteers have 3 vaccinations at 2-week intervals.
testosterone to dihydrotestosterone (DHT), which is
Unlike chemotherapy and radiation, where the
believed to lead to cell hyperplasia. Decreased levels
immune system is compromised, Provenge works to
of DHT lead to decreased glandular cell activity and
produce a stronger immune system to fight disease.
Much about Provenge needs further study. The FDA is presently looking into the viability of this treatment.
Guidance for Parents with School-Age Children Public Health – Dayton & Montgomery County is providing you and your family with the following current and relevant information regarding the upcoming flu season. It is our hope that you share this information and encourage others to follow this guidance to prevent the spread of both seasonal flu and the new H1N1 flu. As you may know, seas
NDA 18-644/S-039 NDA 18-644/S-040 NDA 20-358/S-046 NDA 20-358/S-047 Page 56 (see CLINICAL TRIALS under CLINICAL PHARMACOLOGY). Based on these limited data, it is unknown whether or not the dose of WELLBUTRIN SR needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for maintenance treatme